The purpose of this study was to determine if the sustained release of ampicillin from a biodegradable drug-delivery system (microencapsulated ampicillin anhydrate (MEAA)) will increase or decrease the intensity of a hypersensitivity reaction compared with that observed with free drug. Ovalbumin, which is known to elicit a marked hypersensitivity reaction in guinea pigs, and microencapsulated ovalbumin (MOVA) were tested in parallel with ampicillin and MEAA. Guinea pigs were sensitized biweekly by subcutaneous and intramuscular injections of ampicillin, MEAA, ovalbumin, MOVA or placebo microspheres (test articles), each mixed with Freund's adjuvant, and challenged 2 weeks later, intradermally, with the free compounds. In a separate set of experiments, guinea pigs were sensitized by implantation of the same agents in the caudal thigh of anaesthetized animals. Skin allergic reactions were tested at 1 and 3 weeks following local implantation of the test articles. Sera of sensitized guinea pigs were tested for specific IgG antibodies by enzyme-linked immunosorbent assay, and skin samples from the site of the inflammatory reaction were fixed, stained and evaluated histologically. Guinea pigs sensitized systemically with MEAA or MOVA showed smaller, but not statistically different skin allergic response than animals given corresponding free compounds. However, guinea pigs sensitized by local implantation of MEAA showed a significantly lower inflammatory response (P < 0.0001) than those given an equivalent dose of the free drug. Guinea pigs sensitized with placebo microspheres showed a low inflammatory skin reaction which was similar to those sensitized with all doses of MEAA. There was no significant difference in specific IgG antibody response in the sera of guinea pigs sensitized locally with either free or microencapsulated ampicillin or ovalbumin. Histology of skin revealed a milder inflammatory reaction with MEAA or MOVA than with ampicillin or ovalbumin, respectively. We conclude that the encapsulated ampicillin or ovalbumin and subsequent release of each agent will elicit a reduced hypersensitivity reaction in guinea pigs than will the free agent.
Introduction
Advances in drug delivery over the last decade include the development of a novel local antibiotic delivery system that offers greater efficacy over conventional systemic therapy for the prevention and treatment of infections in soft tissue and bone. [1] [2] [3] The prototype pharmaceutical, microencapsulated ampicillin anhydrate (MEAA), consists of antibiotic encapsulated in the biodegradable polymer poly(DL-lactide-co-glycolide) (PLGA). MEAA is formulated for topical administration to contaminated wounds. As PLGA degrades, high concentrations of the antibiotic are slowly released and maintained within the wound. 1 Animal models of experimental wound infections have consistently shown that MEAA effectively eliminates bacteria from the wound site. 2 Hypersensitivity is a common side-effect of antimicrobial therapy. 4 Parenteral therapy with ampicillin is known to elicit hypersensitivity reactions in allergic patients, 5, 6 local host defence mechanisms are not known. In addition, the effects of PLGA on these same immune phenomena are not known. It is therefore important to determine if treatment with MEAA, from which ampicillin is slowly released from PLGA, will induce a hypersensitivity reaction.
The purpose of this study was to evaluate hypersensitivity reactions in guinea pigs sensitized with free ampicillin and MEAA and then re-challenged with ampicillin. Since ampicillin is a mild sensitizing agent in guinea pigs, 7 animals were also sensitized with ovalbumin, which is known to elicit a strong hypersensitivity response 8 and compared with others sensitized with microencapsulated ovalbumin (MOVA).
Materials and methods

Animals
Male and female Hartley guinea pigs (300-400 g) were purchased from Charles River Laboratories (Wilmington, MA, USA). They were housed in microisolator cages with sterile bedding. The cages were placed in a biological chamber supplied with HEPA-filtered air under positive pressure. Animals were fed Purina Guinea Pig Chow (Klein Feed, Baltimore, MD, USA) and tap water ad libitum. Before surgical procedures guinea pigs were anaesthetized with an im injection (0.4 mL/kg) of a mixture of ketamine 100 mg/mL and xylazine 20 mg/mL (1:0.75). All investigators adhered to the national guidelines for the care of laboratory animals.
Preparation of microencapsulated ampicillin anhydrate
Microencapsulated ampicillin anhydrate (MEAA) used in this study was prepared by the Southern Research Institute (Birmingham, AL, USA) (composite batch D-856-038-1), as previously described. 1 They consisted of 52:48 poly(DL-lactide-co-glycolide) with a core loading dose of 30.7% (w/w) ampicillin anhydrate (diameter 45-150 m) and were sterilized by gamma irradiation. Previous invitro release kinetic studies with this formulation indicated that approximately 25% of the ampicillin is released within 24 h and the remainder over 21 days.
1 Placebo microspheres were prepared in a similar manner except no antibiotic was incorporated into the polymer.
Preparation of microencapsulated ovalbumin
Microencapsulated ovalbumin (MOVA) was prepared with a solvent extraction technique using 1% gelatin. Using ultrasonication (sonicator bath, model SC101, Sonicor, Copiague, NY, USA) and a glass vial, a 5% (w/v) PLGA solution (Sigma, St Louis, MO, USA) was prepared in methylene chloride. A 10% (w/v) ovalbumin/ gelatin solution was prepared (ovalbumin Grade V, Sigma) and a 1% gelatin solution (Vyse Gelatin Co., Schiller Park, IL, USA). An ovalbumin/gelatin/PLGA emulsion was prepared by sonicating 1 part ovalbumin/ gelatin solution and 20 parts PLGA solution (Branson Sonifier 450, Danbury, CT, USA) for 30 s (power setting 4; 20% cycle). The resulting emulsion was added to 250 mL 1.25% polyvinyl alcohol (PVA) solution and mixed at 30°C under vacuum for 90 min. Spheres were collected by filtration and vacuum dried overnight. This methodology provides MOVA with an ovalbumin total core load that is 7.46% of the original weight (determined spectrophotometrically) in 50-150 m diameter microspheres.
Determination of optimum sensitizing and challenging doses
The optimum sensitizing doses of ampicillin, MEAA, ovalbumin and MOVA were determined by injecting guinea pigs (six per group) subcutaneously (sc) with 0.4 mL (0.1 mL in each of four sites on the shaved back) and im with 0.6 mL (0.3 mL in the caudal thigh muscle of each hind leg) using increasing total doses of ampicillin, ovalbumin, MEAA or MOVA (1, 5, 10 and 50 mg/kg body) mixed with 1 : 1 (v/v) Freund's complete adjuvant (FCA) and boosting 2 weeks later with the same sensitizing agent mixed with Freund's incomplete adjuvant (FIA). Placebo microspheres equivalent in weight to the highest dose of MEAA or MOVA with adjuvant were used as negative controls. Two weeks later, animals were challenged intradermally (id) on the shaved back with 0.1 mL of increasing doses (1, 10 and 100 mg/mL) of ampicillin or ovalbumin (one dose at each of three sites) or with 0.1 mL of saline at a fourth site. The inflammatory response (erythema and oedema) was observed at 6, 24 and 48 h in a blind method. The diameter of the wheal and flare reaction was measured with a ruler and scored as follows: 0 no reaction, 1 slight ( 5 mm diameter), 2 moderate (6-10 mm diameter), 3 severe (11-15 mm diameter) and 4 severe with necrosis ( 15 mm diameter), as previously described. 9 For each agent, the concentration of sensitizing antigen that elicited a skin reaction with minimal side-effects, was selected as the optimal sensitizing dose. The concentration of challenging antigen that elicited the strongest skin reaction in animals sensitized with the optimal sensitizing dose and a minimum response in unsensitized animals was selected as the optimal challenging dose.
Evaluation of sensitization by agents implanted into surgical wounds
To evaluate the sensitizing potential of ampicillin, MEAA, ovalbumin or MOVA applied directly into soft tissue, the agents were implanted into surgical wounds. Guinea pigs (six per group) were anaesthetized as previ-ously described after which one hind leg per animal was shaved, sprayed with betadine solution, wiped with an alcohol-soaked gauze pad and allowed to dry. An incision (2.5 cm long 1-2 cm deep) was made into the lateral aspect of the caudal thigh muscle. Increasing doses (5, 50 and 100 mg) of ampicillin or ovalbumin, or an equivalent dose of MEAA, MOVA or placebo microspheres were placed into the incisions, which were closed with surgical staples. Post-surgical pain was alleviated with imbuprenorphine 0.01-0.05 mg/kg. The animals were challenged 1 and 3 weeks later on their shaved backs with an optimum id dose of either ampicillin or ovalbumin. The skin reaction was determined as described above.
Measurement of specific antibody response
After the skin reaction had been scored, sensitized guinea pigs from the surgical wound experiment were anaesthetized and bled by cardiac puncture. Sera were separated and stored at 70°C. All sera were tested for IgG antibodies specific to ampicillin or ovalbumin with an enzyme-linked immunosorbent assay (ELISA). Microtitre plates (Immulon-2, Dynatech, Sterling, VA, USA) were coated with 100 L/well of ampicillin-poly-L-lysine 5 mg/mL or ovalbumin 10 mg/mL in carbonate buffer (pH 9.6) and incubated for 2 h at room temperature and overnight at 4°C. The wells were then washed thrice with 0.1 M phosphate-buffered saline (PBS, pH 7.2) containing 0.05% Tween 20 (T-PBS) and blocked with PBS containing 5% non-fat dry milk (M-PBS) for 1 h at room temperature. The wells were again washed after which 100 L of 10-fold serial dilutions (10 1 -10 6 ) of each guinea pig serum in M-PBS were added and incubated at 37°C for 1 h. Wells were washed as before and 100 L/well of a 10 3 dilution of horseradish-peroxidase-conjugated anti-guinea pig IgG (Sigma) diluted in M-PBS were added and incubated for 1 h at 37°C. The wells were again washed after which 100 L/well of ABTS-peroxidase substrate (Kirkegaard & Perry Labs, Gaithersburg, MD, USA) were added and incubated for 20 min at room temperature. The intensity of the blue-green colour was measured at 405 nm with an ELISA reader (MR 580, Dynatech).
Histopathological evaluation of the inflammatory response
Samples of skin removed from inflammatory sites and caudal thigh muscle from guinea pigs sensitized via a surgical wound were fixed in 10% buffered formalin and processed for routine histology after staining with haematoxylin and eosin. The degree of inflammation was scored as follows: 0 no inflammation; 1 small numbers of acute and/or chronic inflammatory cells; 2 moderate numbers of acute and/or chronic inflammatory cells; 3 marked numbers of acute and/or chronic inflammatory
Statistical analysis
Statistical analysis was performed using Minitab or SAS statistical analysis software programs. Comparison between different groups to determine optimal sensitizing and challenging doses was made using a randomized 2 2 factorial analysis of variance (ANOVA). An ANOVA using a general linear model procedure and a Dunnett's t test were performed to determine differences in the effect of free versus microencapsulated agents implanted into surgical wounds. A 2 3 factorial ANOVA was used to evaluate the differences in the specific antibody response to different treatment and control groups. P values 0 . 0 5 were considered signific a n t .
Results
Determination of optimum sensitizing and challenging doses
The optimal sensitizing doses were ampicillin 10 mg/ kg body wt or an equivalent dose of MEAA (32.5 mg/kg body wt which contains ampicillin 10 mg/kg), and ovalbumin 5 mg/kg body wt or an equivalent dose of MOVA (67 mg/kg body wt). These optimal sensitizing doses required an optimal challenging dose for both ampicillin and ovalbumin of 1 mg. For these optimal doses, guinea pigs sensitized sc and im with MEAA and then challenged with ampicillin showed a lesser, but not significantly different degree of inflammation than guinea pigs sensitized and challenged with ampicillin (0.8 0.44 and 1.2 0.37, respectively) ( Figure 1) . Similarly, guinea pigs sensitized with MOVA exhibited a lesser but not significantly different inflammatory reaction than animals sensitized with free ovalbumin (3.6 0.24 and 4.0 0.0, respectively). Guinea pigs sensitized with free or microencapsulated ovalbumin showed significantly greater inflammatory response than animals sensitized with free or microencapsulated ampicillin, respectively (P 0.001). Placebo microspheres caused only a minimal reaction.
Evaluation of sensitization agents implanted into surgical wounds
Guinea pigs sensitized by surgical implantation of 5, 50 and 100 mg of ampicillin into the caudal thigh muscle incision and re-challenged 1 week later with ampicillin showed a significantly higher inflammatory response than guinea pigs sensitized with an equivalent dose of MEAA (P 0.0001) (Figure 2 ). There was a significant dose response in guinea pigs sensitized with increasing doses of ampicillin but not in animals given equivalent increasing doses of MEAA. Moreover, there was no significant difference in response in guinea pigs sensitized locally with 100 mg of MEAA or placebo microspheres ( Figure  2 ). Comparable results were obtained at 3 weeks after surgical implantation. Guinea pigs sensitized in surgical wounds with 100 or 50 mg ovalbumin or an equivalent dose of MOVA demonstrated a very strong systemic anaphylactic reaction upon re-challenge with ovalbumin, while those sensitized with 5 mg ovalbumin showed a strong hypersensitivity reaction (score 4) upon re-challenge. This cutaneous reaction was less severe in animals sensitized with an equivalent dose of MOVA (score 2).
Measurement of the specific antibody response
Sera from guinea pigs sensitized with ovalbumin or MOVA in surgical wounds had high IgG titres to ovalbumin. Sera from guinea pigs sensitized with ovalbumin 5 mg/kg or its equivalent dose of MOVA showed similar high titres up to 10 5 dilution. Optimum IgG anti-ovalbumin titres were obtained at 10 2 -10 3 dilutions (Figure 3 ). Sera from guinea pigs sensitized with ampicillin or MEAA by local implantation in surgical wounds had much lower titres of IgG antibodies to ampicillin. Figure 4 shows the antibody titre of sera (diluted 1:10) from guinea pigs sensitized with ampicillin 5, 50 and 100 mg/kg doses or an equivalent dose of MEAA. At 5 mg/kg dose, the anti-MEAA titre was greater than the anti-ampicillin titre. At 50 mg/kg dose, the anti-MEAA titre was lower than the anti-ampicillin titre (Figure 4) . However, none of these differences were statistically significant.
Histopathological evaluation of the inflammatory response
Tissue from guinea pigs sensitized with MEAA or placebo microspheres in surgical wounds and challenged with ampicillin showed very mild chronic inflammation with an average score of 1 (Figure 5a ), while tissue from animals sensitized and re-challenged with ampicillin had a generalized mild to moderate chronic dermatitis with an average score of 2 ( Figure 5b ). Tissue from guinea pigs sensitized with MOVA and challenged with ovalbumin had evidence of widespread moderately heavy chronic inflammation through the dermis and subcutaneous fat with an average score of 3 (Figure 5c ), while tissue from animals sensitized and re-challenged with ovalbumin exhibited severe reactions in all cases. These reactions were characterized by focal ulceration, with intense acute and chronic inflammation that extended to the deeper dermis, and abscess formation. Involvement of subcutaneous fat gave a foreign body reaction to extracellular lipid released from damaged lipocytes. The average score for these inflammatory responses was 4 ( Figure 5d) .
Discussion
Previous studies have demonstrated that sensitization of guinea pigs with drugs, including antibiotics, may result in immune responses that can predict the likelihood of allergic reactions in humans. 9, [10] [11] [12] [13] In the present study, the guinea pig model was used to demonstrate that guinea pigs sensitized with a sustained release form of ampicillin or ovalbumin had a reduced, but not significantly different, inflammatory skin response compared with guinea pigs given an equivalent dose of the free agent (Figure 1) . However, guinea pigs sensitized by local implantation of MEAA into a surgical wound showed a significantly decreased inflammatory response compared with animals given free ampicillin (Figure 2 ). In addition, a significant 66 dose-response was obtained with increasing doses of ampicillin but not with equivalent doses of MEAA. This difference in response was not reflected by a significant difference in specific IgG antibody response between the free and the microencapsulated form of ampicillin or ovalbumin (Figures 3 and 4) . Histological examination of skin and muscle sections revealed an increased acute and chronic inflammatory response in guinea pigs sensitized and challenged with ampicillin or ovalbumin compared with animals given MEAA or MOVA ( Figure 5 ).
Our findings agree with previous studies which have demonstrated mild histological and immunological effects of PLGA microspheres. In a study of the biodegradation of, and tissue reaction to PLGA microspheres in rats, there was an initial minimal acute myositis that evolved into a mild connective tissue response.
14 This response was comparable to that elicited by sutures in muscle tissue. Christiansen et al. 15 demonstrated that albumin encapsulated into polylactic/glycolic acid (PLG) microspheres does not provoke an immunological reaction upon repeated injections or cause an adverse reaction when administered to allergic individuals. McGee et al. 8 found higher IgG responses with MOVA than with ovalbumin following sc injection of MOVA to Balb/c mice. Our inability to detect a higher IgG response may be related to the fact that the microspheres used by McGee et al. 8 were 10 m in diameter, which allowed them to be phagocytosed by macrophages, while the MOVA used in this study were 45-150 m in diameter, a size that prevented phagocytosis by macrophages. Also, Tagaki et al. 16 found that ovalbumin encapsulated into PLG microspheres elicited weaker local tissue reactions in guinea pigs than ovalbumin-alum. These investigators suggested that administration of antigens in a controlled sustainedrelease form could become a new immunotherapeutic method for desensitization in allergic disorders. It is possible that the reduced inflammatory response we observed with MEAA or MOVA locally implanted in surgical wounds is due to the slow sustained release of the drugs from the microspheres over an extended timeframe. This effect is similar to the desensitization procedure used in allergic patients, whereby patients receive small quantities of antigen over an extended period of time. We conclude that MEAA causes less of a hypersensitivity reaction in the guinea pig model than ampicillin.
